Poster Session A

Poster Session A
Thursday, October 13
7:00 p.m.-10:00 p.m.

In alphabetical order, not board assignment order

• A combination of trastuzumab/T-DM1, pertuzumab, and bevacizumab causes regression of established xenograft in HER2 amplified breast cancer models, Yuliang Sun, Emory University, Atlanta, GA, United States
• A frequently deleted 6 MB region identified in disseminated cancer cells is associated with poor outcome, Anya Krefft, chair of experimental medicine and therapy research, University of Regensburg, Regensburg, Germany
• A kinome-wide siRNA screen identifies the insulin/IGF-1 receptor pathway as a mechanism of escape from hormone dependence in breast cancer, Emily Fox, Vanderbilt-Ingram Cancer Center, Nashville, TN, United States
• A new and potent strategy to inhibit the growth-promoting HER2/EGFR/RAS signaling pathway in order to block tumorigenesis, invasion and metastasis of highly aggressive human breast cancer, Amy Tang, Eastern Virginia Medical School, Norfolk, VA, United States
• A patient-derived tumor model to study hormone receptor action and luminal specific stem/progenitor cells in estrogen receptor positive breast cancers, Carol Sartorius, University of Colorado Anschutz Medical Center, Aurora, CO, United States
• A role for transmembrane serine protease Hepsin in Ras mediated malignant transformation of MCF10A 2D and 3D cultures, Topi Tervonen, University of Helsinki, Helsinki, Finland
• Aging in humans is associated with increases in progenitor cells and luminal cells with basal characteristics, and a decrease in tumor suppressive myoepithelial cells., Mark LaBarge, Lawrence Berkeley National Laboratory, Berkeley, CA, United States
• Amplified in breast cancer 1 plays a role during initiation and invasive progression of ductal carcinoma in situ, Virginie Ory, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States
• An integrated human mammary epithelial cell (HMEC) system for the study of normal HMEC biology, aging, and transformation, Martha Stampfer, Lawrence Berkeley National Lab, Berkeley, CA United States
• An overactive Par6 pathway sensitizes mammary epithelial cells to transforming growth factor-beta induced apoptosis., Alicia Viloria-Petit, University of Guelph, Guelph, Ontario, Canada
• Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients, Helena Jernstrom, Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
• BCL11A is a basal breast cancer gene and a key regulator of mammary stem cells, Walid Khaled, Wellcome Trust Sanger Institute, Cambridge, England
• Breast cancer patients resistent to hormone therapy show decreased number of cytotoxic supressor cells and have enhanced production of neoangiogenetic and immunosupressive facotrs, Michal Vocka, General Hospital, Charles University, Prague, Czech Republic
• Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in MCF7 cells, Patsy Soon, Kolling Institute of Medical Research, University of Sydney, Sydney, Nsw Australia
• Cap analysis of gene expression reveals genome-wide estrogen signaling in breast cancer cells, Ryonosuke Yamaga, University of Tokyo, Tokyo, Japan
• CDCA3 as a predictor of poor clinical outcome and potential therapeutic target in breast cancer, Zhi Hu, Department of Biomedical Engineering, Oregon Health & Science University, Portland, United States
• Clinical and pre-clinical evidence for combining PI3-kinase/mTOR inhibition with aromatase inhibition in the neoadjuvant treatment of early breast cancer, Zara Ghazoui, Breakthrough Breast Cancer Research Centre, London, United States
• Correlation between change of serum Her-/2neu before and after neoadjuvant chemotherapy and clinical outcomes in advanced breast cancers, JungSun Lee, Haeundae Paik Hopsital, Pusan, Korea (Rep.)
• Coupling tumor suppressor function of LKB1 to regulation of epithelial integrity, Johanna Partanen, University of Helsinki, Helsinki, Finland
• Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition, Elizabeth Musgrove, Garvan Institute of Medical Research, Sydney, Nsw Australia
• Cytoplasmic PELP1 as a biomarker of response the tamoxifen chemoprevention, Julie Ostrander, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States
• Development of an in vivo model of human ductal carcinoma in situ for studying early processes of breast cancer invasive progression, Fariba Behbod, The University Of Kansas Medical Center, Kansas City, KS, United States
• Diet-induced and genetic obesity promote mammary tumor growth in ovariectomized mice, Heekyung Chung, University of California, San Diego, La Jolla, CA, United States
• Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer, Hiroko Yamashita, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
• Effect of chemotherapeutic agents on DNA repair proteins in two breast cancer cell lines, Linn Antberg, Lund University, Lund, Sweden
• Effects of hCG and derived-angiotensin peptides on cell viability and on apoptosis in tumoral (MCF-7) and normal (MCF10A) epithelial breast cells: New therapeutic agents?, Patricia Rozenchan, Escola Paulista de Medicina da Universidade Federal de São Paulo, São Paulo, SP Brazil
• Efferocytosis promotes breast cancer growth and metastasis through MerTK signaling, Rebecca Cook, Vanderbilt University, Nashville, TN, United States
• Elevated expression of squamous cell carcinoma antigen (SCCA) is associated with high grade human breast carcinoma, Joseph Catanzaro, Stony Brook University, Stony Brook, NY, United States
• Epigenetic regulation of cell type-specific gene expression patterns in the human mammary epithelium, Reo Maruyama, Dana-Farber Cancer Institute, Boston, MA, United States
• ER downregulation with fulvestrant in combination with the pan-PI3K inhibitor BKM120 synergizes against ER+/PI3K-mutant breast cancer xenografts in vivo, Todd Miller, Vanderbilt University, Nashville, TN, United States
• ErbB3 expression is required for maintenance of normal and transformed luminal breast epithelial cells, Rebecca Cook, Vanderbilt University, Nashville, TN, United States
• Erythropoietin promotes breast cancer tumorigenicity, Bing Zhou, University of North Carolina Lineberger Cancer Center, Chapel Hill, NC, United States
• Estrogen receptor alpha (ERα) and aryl hydrocarbon receptor (AHR) modulate the transcriptional activity of nuclear factor erythroid 2-related factor 2 (NRF2) in MCF7 breast cancer cells, Raymond Lo, University of Toronto, Toronto, Ontario, Canada
• Functional analysis of epithelial cell adhesion molecule (EpCAM) knockdown in breast cancer, Agnieszka Martowicz, Dept. Of Haematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
• Functional analysis of the matrixmetalloproteinase-11 in tumor growth, angiogenesis and metastasis, Gerold Untergasser, Medical University of Innsbruck, Innsbruck, Austria
• Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyl transferase-1 (NAT1) as a novel prognostic biomarker, Ingrid Hedenfalk, Lund University, Lund, Sweden
• GRB7 is required for triple-negative breast cancer motility, invasion and chemoresistance, Paraic Kenny, Albert Einstein College of Medicine, Bronx, NY, United States
• Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer, Alexander Swarbrick, Garvan Institute of Medical Research, Sydney, Nsw Australia
• Histone demethylase RBP2 promotes tumorigenesis in breast cancer, Jian Cao, Yale University School of Medicine, New Haven, CT, United States
• HPGD associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition and promotes cell migration in cultured breast cancer cells, Laura Lehtinen, VTT Technical Research Centre of Finland and Turku Centre for Biotechnology, Turku, Finland
• Human mesenchymal stem cells activated with TNF-α express TRAIL and induce cell death in MDA-MB-231 breast cancer cells, John Reneau, Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine, Temple, TX, United States
• Hypodiploidy, 1pter loss and inactive X chromosome retention are associated with BRCA1 somatic or germline inactivation in basal-like breast carcinomas, Elodie Manié, Institut Curie, Centre de Recherche, Paris, France
• Identification of microRNAs regulating HER2 signaling, Suvi-Katri Leivonen, VTT Technical Research Centre of Finland, Turku, Finland
• Integrin β5 contributes to the tumorigenic potential of breast cancer cells through two independent signaling pathways, Anna Bianchi-Smiraglia, Roswell Park Cancer Institute, Buffalo, NY, United States
• Interaction of epithelial cells and macrophages in the mammary tumor microenvironment, Laura Bohrer, University of Minnesota, Minneapolis, MN, United States
• JNK2 regulates mammary cell lineage specification in a p53 dependent and independent manner, Carla Van Den Berg, University of Texas, Austin, Austin, TX, United States
• Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1α mediated by the PTEN/PI3K/Akt pathway, Ji-Hye Park, Department of Pathology, College of Medicine, Hanyang University, Seoul, Korea (Rep.)
• Mammalian upstream Hippo signaling pathway proteins activate core pathway kinases and functionally antagonize oncogenic YAP, Paul Reynolds, University of St Andrews, St Andrews, Scotland
• Mammary tumorigenesis in a Notch4 mice lacking one allele of Cripto-1, Maria Cristina Rangel, National Cancer Institute, Bethesda, MD, United States
• miR-495 down-regulates tumor suppressor genes to promote oncogenesis and hypoxia resistance in breast cancer stem cells, Wendy Hwang-Verslues, Academia Sinica, Taipei, Taiwan
• Modeling clonal evolution in mouse tumor xenograft system, Andriy Marusyk, Dana-Farber Cancer Institute, Boston, MA, United States
• Modeling human mammary epithelial cell pathways to oncogenic transformation, James Garbe, Lawrence Berkeley National Laboratory, Berkeley, CA, United States
• Molecular characterization of single EpCAM-positive cells isolated from bone marrow of non-metastatic breast cancer patients, Gundula Haunschild, Chair of Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany
• Myoepithelial cells in normal human breast and in ductal carcinoma in situ (DCIS), Ying Su, Dana-Farber Cancer Institute, Boston, MA United States
• Normal mammary cells influence the growth of breast cancer cells through the ER and PI3K/Akt signaling: Understanding the role of the microenvironment in breast cancer, Maria Riverso, School of Pharmacy University of London, London, England
• Notch pathway in an experimental model of breast cancer metastasis, Nadia Castro, National Cancer Institute, Bethesda, MD, United States
• P120-catenin mediates HER2–induced proliferation and survival of breast cancer cells, Jennifer Yori, Case Western Reserve University, Cleveland, OH, United States
• Pathological complete remission after neoadjuvant chemotherapy predicts improved survival in the various breast cancer subtypes: Systematic review and meta-analyses, Aditya Bardia, Massachusetts General Hospital Cancer Center, Boston, MA, United States
• Patient-derived tumor grafts authentically reflect tumor pathology, growth, metastasis, and disease outcomes, Yoko DeRose, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
• Phosphorylated mTOR and S6 kinase expression predict tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment, Karin Beelen, The Netherlands Cancer Institute, Amsterdam, The Netherlands
• PIAS3 is an acetylation rheostat on the Stat5a chromatin complex, Terry Medler, Northwestern University, Chicago, IL, United States
• Plk2 function in mammary gland development and tumorigenesis, Elizabeth Villegas, Baylor College of Medicine, Houston, TX, United States
• Postpartum mammary gland involution drives DCIS progression through collagen and COX-2, identifying a target for intervention, Traci Lyons, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
• Potential tumor markers in serum of female dogs with mammary neoplasia, Debora Zuccari, Faculty of Medicine FAMERP, São José Do Rio Preto, SP Brazil
• Progesterone and estrogen receptors segregate into different cell subpopulations in the normal human breast, Heidi Hilton, Westmead Institute for Cancer Research, Sydney, Nsw Australia
• Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation, Jenny Vegfors, Linköping University, Linköping, Sweden
• RANK expression in primary tumor tissue at the time of diagnosis correlates with risk of subsequent bone metastases in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657), Jiali Li, University of California San Francisco, San Francisco, CA, United States
• Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases, Kerstin Tiedemann, McGill University, Montreal, QC, Canada
• Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients, Mutsuko Ibusuki, Kumamoto University, Kumamoto, Japan
• Restoration of c-Cbl function, by inhibiting Cdc42, confers tamoxifen sensitivity on basal-like (triple negative) breast cancer cells, Hsing-Yu Chen, University of Rochester Medical Center, Rochester, NY, United States
• Ribavirin growth inhibition of breast cancer cells and the role of eIF4E phosphorylation, Filippa Pettersson, Lady Davis Institute and Segal Cancer Centre of the Jewish General Hospital, Montreal, Quebec, Canada
• ROCK1 inhibition promotes propagation of mouse mammary epithelial tumor initiating cells in culture and inhibits spontaneous epithelial-mesenchymal transition, David Castro, Sanford-Burnham Medical Research Institute, La Jolla, CA, United States
• Role of the transcription factor FOXP3 in cancer metastasis, Patrizia Casalini, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
• Significant telomere shortening is common in luminal epithelial cells in histologically normal breast tissues from women without cancer, Christopher Heaphy, Johns Hopkins University School of Medicine, Baltimore, MD, United States
• Simultaneous and stable RNAi of HER2 and PTK6 led to synergistic reduction of cancer progression in breast cancer cells, Natalie Ludyga, Helmholtz Zentrum Muenchen, Neuherberg, Germany
• Single molecule studies reveal insights on the nature of constitutively activated HER2, Inhee Chung, Genentech, Inc, South San Francisco, CA, United States
• S-phase kinase-associated protein 2 in triple-negative and basal-like breast cancers, Katerina Fagan-Solis, University of Massachusetts Amherst, Amherst, MA, United States
• Squamous cell carcinoma antigen 1 (SCCA1) promotes apoptosis in response to ER stress, Namratha Sheshadri, Stony Brook University, Stony Brook, NY, United States
• Stanniocalcin 2 in PyV MT-induced mammary tumorigenesis, Andy Chang, Children's Medical Research Institute, Westmead, New South Wales, Australia
• TAK1-TAB2 signaling contributes to bone metastasis by breast carcinoma cells, Andrei Bakin, Roswell Park Cancer Institute, Buffalo, NY, United States
• Targeting integrin signaling to suppress invasive recurrence post-ionizing radiation (IR) in a 3D cell culture model of ductal carcinoma in situ, Jin-Min Nam, Hokkaido University, Sapporo, Japan
• Targeting PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer, Valerie Cortez, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States
• The antiestrogen ICI 182.780 inhibits progestin induced cell proliferation by blocking the genomic interaction between ERα and PR at the CCND1/MYC promoters, Sebastian Giulianelli, Institute of Experimental Biology and Medicine (IBYME), CONICET, Buenos Aires, Argentina
• The FRY tumor suppressor gene, a novel inhibitor of epithelial mesenchymal transition, is a putative biomarker of breast cancer progression and clinical outcomes., Helmut Zarbl, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, United States
• The prognostic value of MARCKS-like1 in lymph node negative breast cancer, Kristin Jonsdottir, Department of Pathology, Stavanger University Hospital and University of Bergen, Stavanger, Norway
• The role of androgen receptor in postmenopausal breast cancer, Jennifer Richer, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
• The role of angiocrine signaling in breast tumor proliferation and motility, Dana Brantley-Sieders, Vanderbilt University Medical Center, Nashvlle, TN, United States
• The role of genetic breast cancer susceptibility loci as prognostic factors, Marjanka Schmidt, Netherlands Cancer Institute, Amsterdam, The Netherlands
• The role of WNT10B in triple-negative breast cancer, Peter Wend, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Los Angeles, CA, United States
• The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation, Olga Anczuków, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States
• TMEM (Tumor MicroEnvironment of Metastasis) in human breast cancer: an intravasation microenvironment unrelated to intratumoral lymphatics, Paula Ginter, Weill Cornell Medical College, New York, NY, United States
• Towards a personalized therapy: targeting the receptor tyrosine kinases RET to overcome endocrine therapy resistance in breast cancer, Andrea Morandi, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, England
• Triple-negative breast cancer in Algerian patients: prevalence, age at diagnosis and association with menopausal status, Farid Cherbal, USTHB, Algiers, Algeria
• Unconventional DNA replication as a prognostic signature in breast cancer, Christophe Cazaux, Cancer Research Center of Toulouse INSERM and University of Toulouse, Toulouse, France